BofA lowered the firm’s price target on Envista (NVST) to $23 from $26 and keeps a Buy rating on the shares. The focus on Q1 earnings should be on sequential trends in the U.S. implant business, Spark profitability, margin progress, and any impact to the China business, the analyst tells investors in a preview. Ahead of earnings, the firm lowered its Q1 and FY25 revenue and EBITDA estimates.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVST:
- Envista price target lowered to $15 from $18 at Mizuho
- Envista price target lowered to $16 from $19 at Morgan Stanley
- Envista price target lowered to $21 from $23 at UBS
- Envista price target lowered to $19 from $21 at Wells Fargo
- Positive Outlook for Envista Holdings: Strategic Growth and Strong Brand Drive Buy Rating